Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
NCT06151561
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Moderate to Severe Glabellar Lines
Interventions
DRUG:
AGN-151586
DRUG:
Placebo
Sponsor
AbbVie